Development of predictive models of proliferative vitreoretinopathy based on genetic variables: The retina 4 project

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 5, 2009, Pages 2384-2390

  Rojas, Jimena ^a   Fernandez, Itziar ^b   Pastor, J Carlos ^a   Garcia Gutierrez, Maria Teresa ^a   Sanabria, Rosa Maria ^a   Brion, Maria ^c   Sobrino, Beatriz ^d   Manzanas, Lucia ^e   Giraldo, Antonio ^e   Rodriguez de la Rua, Enrique ^a   Carracedo, Angel ^f  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d Centro Nacional de Genotipado (CeGen)   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^f UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN 1A; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1RN; INTERLEUKIN 6; INTERLEUKIN 8; MATRILYSIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN MIF; PROTEIN PI3KCG; SCATTER FACTOR; SMAD3 PROTEIN; SMAD7 PROTEIN; SOMATOMEDIN B; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; EYE PROTEIN;

ALGORITHM; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GENE EXPRESSION PROFILING; GENE LOCUS; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MACHINE LEARNING; MAJOR CLINICAL STUDY; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; REPRODUCIBILITY; RETINA DETACHMENT; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SUPPORT VECTOR MACHINE; VALIDATION PROCESS; VITREORETINOPATHY; ARTIFICIAL INTELLIGENCE; BIOLOGICAL MODEL; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; DECISION TREE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; MULTICENTER STUDY; PREDICTION AND FORECASTING;

ALGORITHMS; ARTIFICIAL INTELLIGENCE; DECISION TREES; DIAGNOSIS, COMPUTER-ASSISTED; EYE PROTEINS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RETINAL DETACHMENT; VITREORETINOPATHY, PROLIFERATIVE;

EID: 65549097275     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2670     Document Type: Article

References (37)

1. Pastor JC, Rodriguez de la Rua E, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21:127-144.
2. Pastor JC, Fernandez I, Rodriguez de la Rua E, et al. Surgical outcomes for primary rhegmatogenous retinal detachments in phakic and pseudophakic patients: The Retina 1 Project-report 2. Br J Ophthalmol. 2008;92:378-382.
3. Asaria RH, Charteris DG. Proliferative vitreoretinopathy: developments in pathogenesis and treatment. Compr Ophthalmol Update. 2006;7:179-185.
4. Charteris DG, Sethi CS, Lewis GP, Fisher SK. Proliferative vitreoretinopathy: developments in adjunctive treatment and retinal pathology. Eye. 2002;16:369-374.
5. Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001;108:1179-1183.
6. Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RH, Bunce C., and the PVR Study Group. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. 2004;111:2240-2245.
7. Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 2007;114:698-704.
8. Kon CH, Occleston NL, Aylward GW, Khaw PT. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci. 1999;40:705-712.
9. Kon CH, Asaria RH, Occleston NL, Khaw PT, Aylward GW. Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. Br J Ophthalmol. 2000;84:506-511.
10. Asaria RH, Kon CH, Bunce C, et al. How to predict proliferative vitreoretinopathy: a prospective study. Ophthalmology. 2001;108: 1184-1186.
11. Rodriguez de la Rua E, Pastor JC, Aragon J, et al. Interaction between surgical procedure for repairing retinal detachment and clinical risk factors for proliferative vitreoretinopathy. Curr Eye Res. 2005;30:147-153.
12. Sanabria Ruiz-Colmenares MR, Pastor Jimeno JC, Garrote Adrados JA, Telleria Orriols JJ, Yugueros Fernandez MI. Cytokine gene polymorphisms in retinal detachment patients with and without proliferative vitreoretinopathy: a preliminary study. Acta Ophthalmol Scand. 2006;84:309-313.
13. Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112:159-165.
14. Wiedemann P. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol. 1992;36:373-384.
15. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43:3-18.
16. El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ. Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br J Ophthalmol. 2001;85:461-470.
17. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
18. Cover TM, Thomas JA. Entropy, Relative Entropy and Mutual Information: Elements of Information Theory. New York: John Wiley; 1991:12-49.
19. Welch WJ. Construction of permutation test. J Am Stat Assoc. 1990;85:693-698.
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Methodol. 1995;57:289-300.
21. Duda RO, Hart PE. Bayes Decision Theory. Pattern Classification and Scene Analysis. New York: John Wiley & Sons 1973;10-43.
22. Burges CJC. A tutorial on support vector machines for pattern recognition. Data Min Knowl Disc. 1998;2:121-167.
23. Breiman LF, Friedman JH, Losen RA, Stone CJ. Classification and Regression Trees. New York: Chapman & Hall 1984.
24. Breiman LF. Random forests. Mach Learn. 2001;45:5-32.
25. Díaz-Uriarte R, Álvarez de Andrés S. Gene selection and classification of microarray data using random forest. BMC Bioinform. 2006;7:3.
26. R Development Core Team (2007). R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2007, Available at http://www.R-project. org. Accessed April 2007.
27. Joussen AM, Joeres S, Fawzy N, et al. Autologous translocation of the choroid and retinal pigment epithelium in patients with geographic atrophy. Ophthalmology. 2007;114:551-560.
28. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004;22:929-979.
29. Arend WP. Interleukin 1 receptor antagonist: a new member of the interleukin 1 family. J Clin Invest. 1991;88:1445-1451.
30. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE. 2006;357:re13.
31. Böttner M, Krielglstein K, Unsicker K. The transforming growth factor-betas: structure, signaling, and roles in nervous system development and functions. J Neurochem. 2000;75:2227-2240.
32. Sheppard D. Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc. 2006;3:413-417.
33. Goetz FW, Planas JV, MacKenzie S. Tumor necrosis factors. Dev Comp Immunol. 2004;28:487-497.
34. Guidry C. The role of Muller cells in fibrocontractive retinal disorders. Prog Retin Eye Res. 2005;24:75-86.
35. Pastor JC, Mendez MC, de la Fuente MA, et al. Intraretinal immunohistochemistry findings in proliferative vitreoretinopathy with retinal shortening. Ophthalmic Res. 2006;38:193-200.
36. De la Vega FM, Lazaruk KD, Rhodes MD, Wenz MH. Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping System. Mutat Res. 2005;573:111-135.
37. Dai Z, Papp AC, Wang D, Hampel H, Sadee W. Genotyping panel for assessing response to cancer chemotherapy. BMC Med Genomics. 2008;1:24.